Company: PACB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001299130-25-000156
Chunk: 62

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 62
---
370 $— $— $55,370 Investments:Corporate debt securities — 31,064 — 31,064 — 46,905 — 46,905 U.S. government & agency securities— 228,868 — 228,868 — 287,656 — 287,656 Total investments — 259,932 — 259,932 — 334,561 — 334,561 Short-term restricted cash300 — — 300 690 — — 690 Long-term restricted cash1,532 — — 1,532 1,532 — — 1,532 Total assets measured at fair value $53,156 $263,411 $— $316,567 $57,592 $334,561 $— $392,153 LiabilitiesContingent consideration$— $— $— $— $— $— $18,700 $18,700 Total liabilities measured at fair value $— $— $— $— $— $— $18,700 $18,700 During the six months ended June 30, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.Contingent ConsiderationIn connection with the August 2023 Apton Biosystems, Inc. (“Apton”) acquisition, contingent consideration of $25.0 million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0 million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition. The number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the twenty trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does